Basic Information
| LncRNA/CircRNA Name | SAP30L-AS1 |
| Synonyms | NA |
| Region | GRCh38_5:154329437-154445850 |
| Ensemble | ENSG00000245275 |
| Refseq | NR_037897 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot |
| Sample | cell line (LNCaP) |
| Expression Pattern | up-regulated |
| Function Description | The levels of SAP30L-AS1 were upregulated in benign prostatic hyperplasia (BPH).SAP30L-AS1 and SChLAP1 had adequate diagnostic value to distinguish PCa from controls. Two lncRNAs separately combined with prostate specific antigen (PSA) possessed a moderate ability for discrimination.SAP30L-AS1 expression level was related to PSA values and tumor invasion,may lead to the identification of suitable biomarkers, with potential diagnostic utility |
| Pubmed ID | 29614511 |
| Year | 2018 |
| Title | Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer. |
External Links
| Links for SAP30L-AS1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |